A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies

Clinical trial NCT03088878 · COMPLETED

Trial details

NCT number: NCT03088878
Sponsor: Oncternal Therapeutics, Inc
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

B-cell Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Mantle Cell Lymphoma Marginal Zone Lymphoma

Start date: 2018-01-03
Primary completion: 2024-09-25
Enrollment: 95

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.